Lantern Pharma board nominee Maria Maccecchini; director Leslie Kreis not standing for reelection

Lantern Pharma Inc.

Leslie W. Kreis, Jr. will not stand for reelection at the June 8, 2022 annual meeting.
Maria L. Maccecchini, Ph.D., CEO of Annovis Bio (ANVS), nominated to the board.
She brings over 30 years biopharma experience in neurodegenerative disease and drug development.
Kreis served since 2019; CEO Panna Sharma thanked him for guiding Lantern through IPO and growth.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leslie W. Kreis, Jr.

Director

LTRN · Lantern Pharma Inc.

Filed: April 26, 2022, 7:59 PM ET

On April 20, 2022, Leslie W. Kreis, Jr. notified Lantern Pharma Inc. (the “Company”) that he will not stand for reelection to the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leslie W. Kreis, Jr. departed as Director at Lantern Pharma Inc..

Action: will not stand for reelection
Role: Director

Exact text from the filing

On April 20, 2022, Leslie W. Kreis, Jr. notified Lantern Pharma Inc. (the “Company”) that he will not stand for reelection to the Company’s Board of Directors.

View on SEC.gov

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-021526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.